Chest
Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Section snippets
Results of a systematic review of randomized trials of oral vitamin K antagonist (VKA) therapy vs no antithrombotic therapy:
Investigators from the five primary prevention trials pooled their data after standardizing clinical definitions.6 The individual studies and their results are summarized in Tables 2345.1213141516 The results of individual-subject meta-analyses of these trials and later trials with pooled data are provided in Table 6. The clinical trials included patients with chronic persistent (also known as “sustained,” and including the category “permanent”17) or, less commonly, paroxysmal AF (PAF)
Recommendations
1.1.1. In patients with persistent (also known as “sustained,” and including patients categorized as “permanent” in certain classification schemes17) or paroxysmal (intermittent) AF at high risk of stroke (ie, having any of the following features: prior ischemic stroke, TIA, or systemic embolism, age > 75 years, moderately or severely impaired left ventricular systolic function and/or congestive heart failure, history of hypertension, or diabetes mellitus), we recommend anticoagulation with an
Recommendation
1.2. For patients with atrial flutter, we suggest that antithrombotic therapy decisions follow the same risk-based recommendations as for AF (Grade 2C).
Recommendations
1.3.1. For patients with AF and mitral stenosis, we recommend anticoagulation with an oral VKA, such as warfarin (target INR, 2.5; range, 2.0 to 3.0) [Grade 1C+].
1.3.2. For patients with AF and prosthetic heart valves, we recommend anticoagulation with an oral VKA, such as warfarin (Grade 1C+).
Remark: The target intensity of anticoagulation may be INR 3.0 (range, 2.5 to 3.5), ie, higher than the usual target INR of 2.5 (range, 2.0 to 3.0), and it may be appropriate to add aspirin, depending on
Recommendation
1.4. For AF occurring shortly after open-heart surgery and lasting > 48 h, we suggest anticoagulation with an oral VKA, such as warfarin, if bleeding risks are acceptable (Grade 2C). The target INR is 2.5 (range, 2.0 to 3.0). We suggest continuing anticoagulation for several weeks following reversion to NSR, particularly if patients have risk factors for thromboembolism (Grade 2C).
2.1 Anticoagulation for elective cardioversion of AF
Four decades have passed since synchronized capacitor discharge was first introduced by Lown and coworkers152153154 for the rapid termination of atrial and ventricular tachyarrhythmias. Systemic embolism is the most serious complication of cardioversion and may follow external or internal direct current (DC), pharmacologic, and spontaneous cardioversion of AF. Evidence favoring the efficacy of anticoagulation is based on observational studies. The large reported efficacy from such studies has
Recommendations
2.1.1. For patients with AF of ≥ 48 h or of unknown duration for whom pharmacologic or electrical cardioversion is planned, we recommend anticoagulation with an oral VKA, such as warfarin (target INR, 2.5; range, 2.0 to 3.0), for 3 weeks before elective cardioversion and for at least 4 weeks after successful cardioversion (Grade 1C+).
Remark: This recommendation applies regardless of a patient's risk factor status. Continuation of anticoagulation beyond 4 weeks is based on whether the patient
1.1 Atrial fibrillation
1.1.1. In patients with persistent (also known as “sustained,” and including patients categorized as “permanent” in certain classification schemes17) or paroxysmal (intermittent) AF at high risk of stroke (ie, having any of the following features: prior ischemic stroke, TIA, or systemic embolism, age > 75 years, moderately or severely impaired left ventricular systolic function and/or congestive heart failure, history of hypertension, or diabetes mellitus), we recommend anticoagulation with an
ACKNOWLEDGMENT
We are grateful to Margaret C. Fang, MD, MPH, for help reviewing the relevant literature and for reviewing early drafts of this chapter.
References (199)
- et al.
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
Am J Cardiol
(1994) - et al.
Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota
Mayo Clin Proc
(1990) - et al.
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation
Lancet
(1989) - et al.
Canadian atrial fibrillation anticoagulation (CAFA) study
J Am Coll Cardiol
(1991) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study
Lancet
(1994)- et al.
European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the prevention of stroke
J Neurol Sci
(1996) - et al.
Alternate-day dosing of aspiring in atrial fibrillation. LASAF Pilot Study Group
Am Heart J
(1999) - et al.
The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation
Am Heart J
(1992) - et al.
Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
Am J Cardiol
(1998) - et al.
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial
Lancet
(2002)
The oral direct thrombin inhibitor, ximelagatran, and its active form, melagatran, in ascending doses compared with dalteparin for prevention of venous thromboembolism after total hip or total knee replacement: the METHRO II study
Lancet
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
Am Heart J
Active- control clinical trials to establish equivalence or non-inferiority: methodological and statistical concepts linked to quality
Am Heart J
Thyrotoxicosis, atrial fibrillation, and embolism, revisited
Am Heart J
Antithrombotic therapy in atrial fibrillation
Chest
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation
Am J Med
Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study
J Am Coll Cardiol
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy
J Am Coll Cardiol
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
JAMA
Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications
Arch Intern Med
Atrial fibrillation and mortality in an elderly population
Aust N Z J Med
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials
Arch Intern Med
Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Heart Study
Arch Intern Med
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study
Stroke
Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation
Neurology
Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease
BMJ
Accuracy of transesophageal echocardiography for identifying left atrial thrombi: a prospective, intraoperative study
Arch Intern Med
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
N Engl J Med
Stroke Prevention in Atrial Fibrillation study: final results
Circulation
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
N Engl J Med
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Circulation
Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
N Engl J Med
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
Lancet
Stroke Prevention in Atrial Fibrillation II study [letter]
Lancet
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
Lancet
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: The AFASAK 2 Study
Arch Intern Med
Bleeding during antithrombotic therapy in patients with atrial fibrillation
Arch Intern Med
Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors
Neurology
Risk factors for intracranial hemorrhage in outpatients taking warfarin
Ann Intern Med
Optimal oral anticoagulant therapy in patients with mechanical heart valves
N Engl J Med
Letter to the editor
J Neurol Sci
Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
Arch Intern Med
The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials
Arch Intern Med
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis
Ann Intern Med
Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs
J Gen Intern Med
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin
BMJ
Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation-an individual patient meta-analysis
JAMA
Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation Investigators
Neurology
Cardioembolic versus noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies
Cerebrovasc Dis
Impact of intensity of oral anticoagulation on stroke severity and stroke mortality in patients with non-valvular atrial fibrillation
N Engl J Med
Cited by (530)
Carbon based nanomaterials for the detection of narrow therapeutic index pharmaceuticals
2021, TalantaCitation Excerpt :The second procedure supplied a fast, low-cost, simple, ultrasensitive and reproducible method for detection of digoxin with ultra-low limit of detection, 7.95 ± 0.22×10−12 mol/L. Both of the developed luminescent apta-nano-biosensors were applied for qualification of target molecule in urine and human serum with acceptable analytical results [59]. Warfarin (WAR, 3-(α-acetonylbenzyl)-4-hydroxycoumarin) is broadly utilized as a blood anticoagulant in a variety of cerebrovascular and cardiovascular disorders like atrial fibrillation, pulmonary embolism, venous thromboembolism, coronary heart diseases and valvular heart disease for preventing and treatment of diseases [60–62]. Warfarin has narrow therapeutic index and required careful controlling of the patients.
Medication with caution: Analysis of adverse reactions caused by a combination of Chinese medicine and warfarin sodium tablets
2020, Journal of EthnopharmacologyAntiplatelet drugs in the management of cerebral ischemia
2019, PlateletsFacile and sensitive electrochemical sensing device based on carbon paste electrode for warfarin determination
2024, Monatshefte fur Chemie